Trial Profile
A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Plozalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Takeda Oncology
- 20 Sep 2010 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
- 20 Sep 2010 New source identified and integrated (ClinicalTrials.gov record NCT01199640).
- 11 Nov 2005 New trial record.